ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Phase 2

LL-37

LL-37

Also known as: Cathelicidin, hCAP-18 Fragment, CAMP

Overview

Key Facts

Primary Goal: The only human cathelicidin, a 37-amino acid antimicrobial peptide cleaved from the C-terminus of hCAP-18

The only human cathelicidin, a 37-amino acid antimicrobial peptide cleaved from the C-terminus of hCAP-18. Functions as a critical component of innate immunity with direct pathogen-killing activity and potent immunomodulatory effects. Half-Life ~4 hours Typical Dose 50–100 mcg Frequency 1x daily or every other day Cycle Length 4-8 weeks

Dosing Information

Half-Life

~4 hours

Typical Dose

50–100 mcg

Frequency

1x daily or every other day

Cycle Length

4-8 weeks

Administration Routes:

subcutaneoustopical

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration1-2 weeks

Research Summary

Phase 2

Extensively studied innate immune peptide with over 2,000 published papers. Phase 1 clinical trials conducted for chronic wound healing (OP-145, a derivative). Strong preclinical data for biofilm-associated infections, diabetic wound healing, and adjunct antibiotic therapy. Vitamin D-dependent expression explains some immune benefits of vitamin D supplementation.

Frequently Asked Questions

Common questions about LL-37

UK-Specific Information

Exclusive data points and guidance for UK residents using LL-37

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With